Efficacy and Safety of AGN-199201 in Patients With Persistent Erythema Associated With Rosacea

Trial Profile

Efficacy and Safety of AGN-199201 in Patients With Persistent Erythema Associated With Rosacea

Completed
Phase of Trial: Phase III

Latest Information Update: 30 Jan 2018

At a glance

  • Drugs Oxymetazoline (Primary)
  • Indications Erythema
  • Focus Therapeutic Use
  • Acronyms REVEAL 1
  • Sponsors Allergan
  • Most Recent Events

    • 30 Jan 2018 Primary endpoint (Percentage of Patients With at Least a 2-Grade Decrease From Baseline on Both Clinician Erythema Assessment (CEA) and Subject Satisfaction Assessment (SSA) 5-point Scales) has been met as per the results published in the Journal of the American Academy of Dermatology
    • 30 Jan 2018 Results (n=885) of pooled analysis of REVEAL 1 and REVEAL 2 trials assessing safety and efficacy published in the Journal of the American Academy of Dermatology
    • 10 Jun 2017 Biomarkers information updated
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top